Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
Status:
Completed
Trial end date:
2011-03-29
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia, Europe, Japan and North America. The aim of this clinical
trial is to investigate the safety and the efficacy of a prophylactic treatment option with
long acting coagulation factor VII (LA-rFVIIa) for haemophilia patients with inhibitors.